therapeutics more specifically the compounds of the invention are inhibitors of the faah enzyme and therefore can be used for the treatment of various disorders associated with faah enzyme which include in a non limiting manner pain eating disorders neurological and psychiatric pathologies among other disorders application_number US 47328406 A description among the compounds of general formula i a first sub group of compounds consists of compounds for which r 1 represents a group chosen especially from a phenyl pyridyl pyrimidinyl pyrazinyl naphthyl quinolyl isoquinolyl benzisoxazolyl thienopyridyl this group being optionally substituted with one or more groups r 3 more particularly with one or two groups r 3 which may be identical or different and or r 2 represents a group of general formula chr 5 conhr 6 and or r 3 represents a halogen atom more particularly a chlorine a bromine or a fluorine or a cyano group c 1 6 alkyl more particularly a methyl ethyl n propyl or isobutyl c 1 6 alkoxy more particularly a methoxy c 1 6 fluoroalkyl more particularly a cf 3 c 1 6 fluoroalkoxy more particularly an u2014 och 2 cf 3 u2014 o u2014 c 2 3 alkylene more particularly an u2014 o u2014 ch 2 3 u2014 phenyloxy and or r 6 represents a hydrogen atom or a c 1 6 alkyl group more particularly a methyl among the compounds of general formula i a second sub group of compounds consists of compounds for which r 1 represents a group chosen especially from a pyridyl pyrimidinyl pyrazinyl quinolyl and isoquinolyl this group being optionally substituted with a group r 3 and or.